Company Encyclopedia
View More
name
Biorestorative Therapies
BRTX.US
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company’s products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.
1.935 T
BRTX.USMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking321/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-208.21%E
    • Profit Margin-3304.77%E
    • Gross Margin10.42%E
  • Growth ScoreD
    • Revenue YoY1.70%C
    • Net Profit YoY-31.34%D
    • Total Assets YoY-61.28%E
    • Net Assets YoY-77.91%E
  • Cash ScoreC
    • Cash Flow Margin-3.03%D
    • OCF YoY1.70%C
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreD
    • Gearing Ratio60.89%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Down 2.7% - Time to Sell?

    BioRestorative Therapies (OTCMKTS:BRTXQ) shares fell 2.7% to $1.08, with trading volume significantly lower than average. The stock's fifty-day moving average is $1.40, and its two-hundred-day moving average is $1.53. Analysts currently rate the stock as Hold, but suggest other stocks may be better investments.

    Market Beat·
    US
    BRTX
    +0.86%
    Market Beat·
    US
    BRTX
    +0.86%

    BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation

    BioRestorative Therapies Inc. has unveiled its regenerative medicine pipeline and commercial plans in a new investor presentation. The company is progressing with mid-stage clinical programs using BRTX-100 and preclinical research on ThermoStem. It is also advancing biologics-based cosmetic products with a five-year agreement with Cartessa Aesthetics. Key market opportunities include the global cosmetic and injectable markets, supported by their cGMP ISO 7 certified facility. Ongoing Phase 2 clinical trials target musculoskeletal conditions. The presentation was published on November 21, 2025.

    Reuters·
    US
    BRTX
    +0.86%
    Reuters·
    US
    BRTX
    +0.86%

    U.S. stock market midday update: FDA approval and expansion plans fail to boost, BioRestorative Therapies down 23.78%

    Biorestorative Therapies fell 23.78%; Precision BioSciences rose 17.77%, with a transaction volume of USD 3.201 billion; Regeneron Pharmaceuticals rose 5.04%, with a transaction volume of USD 334 million; AbbVie fell 1.02%, with a transaction volume of USD 144 million; Amgen fell 1.05%, with a market capitalization of USD 182.4 billion

    Tracking Unusual Activity·
    US
    BRTX
    +0.86%
    Tracking Unusual Activity·
    US
    BRTX
    +0.86%

    BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease

    MELVILLE, N.Y., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- BioRestorative Therapies, Inc. ( "BioRestorative", "BRTX" or the "Company" ) ( NASDAQ:BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it has been granted a Type B meeting with ...

    GlobeNewswire·
    US
    BRTX
    +0.86%
    GlobeNewswire·
    US
    BRTX
    +0.86%

    BioRestorative Therapies: Promising Clinical Advances and Strategic Growth Drive Buy Rating

    Michael Okunewitch from Maxim Group maintains a Buy rating on BioRestorative Therapies with an $8.00 price target. The rating is based on promising clinical advances, particularly the BRTX-100 cell therapy for chronic lumbar disc disease, and strategic growth plans, including expansion into cervical spinal pain treatment. The company's stable financial position and leadership in biocosmeceuticals further support the positive outlook. Okunewitch's average return is -5.0% with a 37.50% success rate on recommended stocks.

    Tip Ranks·
    US
    BRTX
    +0.86%
    Tip Ranks·
    US
    BRTX
    +0.86%
    © 2025 Longbridge｜Disclaimer